Emory University
The Pre-eclampsia Screening Trial to Improve Outcomes (PRESTO) research study aims to assess how clinicians use a blood test to guide care decisions in determining preeclampsia risk, with the overall aim of improving outcomes for both pregnant persons and their babies. The study will evaluate whether a blood test can help doctors better identify pregnant patients with hypertensive disorders of pregnancy who are at risk of developing severe pre-eclampsia, which is a serious pregnancy condition that can affect organs such as the liver and kidneys and often leads to preterm delivery. The lab test measures two naturally occurring proteins in the blood that help estimate short-term risk for worsening disease. The goal is to determine whether providing this lab test result to clinicians can improve outcomes including safely prolong pregnancy, reduce unnecessary preterm deliveries, improve newborn outcomes, and optimize hospital care, without increasing complications for pregnant women or causing excess risks to the baby.
Participants will receive standard clinical care and will have a small blood sample drawn for the lab test. This study will have two phases: Phase A - the pre-phase and Phase B- the post-phase. The difference in the phases is whether test results are shared with doctors. Depending on when their hospital enters the study and which phase they are enrolled in, clinicians may or may not receive the test result, allowing researchers to compare outcomes before and after use of the test. Enrolled participants in both phases will have a blood draw, and data will be collected about their pregnancy and…
Inclusion Criteria: * Pregnant persons aged 18 years or older. * Singleton pregnancy. * Gestational age from 23 weeks 0 days through 33 weeks 6 days. * Presentation to obstetric triage or hospitalization for a hypertensive disorder of pregnancy. * Provision of signed informed consent (English- or Spanish-speaking). Exclusion Criteria: * Enrollment in another therapeutic interventional trial with a primary outcome of HDP * Receipt of intravenous heparin during hospitalization. * Planned delivery upon admission for HDP within 48 hours of admission (If a patient is admitted with no immediate p…
Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.
sFlt-1/PlGF measurements will be available to clinicians in real time and may be incorporated into clinical management according to the FDA-approved algorithm